Gateway Investment Advisers LLC acquired a new stake in shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 198,514 shares of the company’s stock, valued at approximately $4,044,000.
Other large investors also recently made changes to their positions in the company. Heritage Investors Management Corp purchased a new stake in shares of Takeda Pharmaceutical in the first quarter valued at $3,724,000. Neville Rodie & Shaw Inc. purchased a new stake in shares of Takeda Pharmaceutical in the first quarter valued at $475,000. Dumont & Blake Investment Advisors LLC purchased a new stake in shares of Takeda Pharmaceutical in the first quarter valued at $230,000. Huntington National Bank purchased a new stake in shares of Takeda Pharmaceutical in the first quarter valued at $134,000. Finally, Vigilant Capital Management LLC purchased a new stake in shares of Takeda Pharmaceutical in the first quarter valued at $63,000. Institutional investors own 3.45% of the company’s stock.
TAK opened at $19.04 on Friday. The firm has a market capitalization of $30.51 billion, a PE ratio of 17.79 and a beta of 0.73. Takeda Pharmaceutical Co Ltd has a 12-month low of $15.50 and a 12-month high of $23.95. The company has a quick ratio of 2.81, a current ratio of 3.06 and a debt-to-equity ratio of 1.19.
Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Friday, February 1st. The company reported $0.75 earnings per share (EPS) for the quarter. The company had revenue of $4.43 billion during the quarter. Takeda Pharmaceutical had a return on equity of 14.62% and a net margin of 6.13%. Sell-side analysts anticipate that Takeda Pharmaceutical Co Ltd will post 0.47 EPS for the current fiscal year.
TAK has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a report on Wednesday, March 13th. Goldman Sachs Group restated a “buy” rating on shares of Takeda Pharmaceutical in a report on Tuesday, March 19th.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Highlight Press and is owned by of Highlight Press. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://highlightpress.com/2019/04/14/gateway-investment-advisers-llc-acquires-new-stake-in-takeda-pharmaceutical-co-ltd-tak.html.
Takeda Pharmaceutical Profile
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Featured Story: Book Value Per Share – BVPS
Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co Ltd (NYSE:TAK).
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.